GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Earnings per Share (Diluted)

MDxHealth (MDxHealth) Earnings per Share (Diluted) : $-1.49 (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is MDxHealth Earnings per Share (Diluted)?

MDxHealth's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.49.

MDxHealth's EPS (Basic) for the three months ended in Mar. 2024 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.49.

MDxHealth's EPS without NRI for the three months ended in Mar. 2024 was $-0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.49.

During the past 3 years, the average EPS without NRIGrowth Rate was 26.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.70% per year.

During the past 13 years, MDxHealth's highest 3-Year average EPS without NRI Growth Rate was 30.90% per year. The lowest was -34.20% per year. And the median was 13.50% per year.


MDxHealth Earnings per Share (Diluted) Historical Data

The historical data trend for MDxHealth's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth Earnings per Share (Diluted) Chart

MDxHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.90 -3.40 -2.38 -2.78 -1.66

MDxHealth Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.39 -0.40 -0.39 -0.31

Competitive Comparison of MDxHealth's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, MDxHealth's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MDxHealth's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's PE Ratio distribution charts can be found below:

* The bar in red indicates where MDxHealth's PE Ratio falls into.



MDxHealth Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

MDxHealth's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-43.1-0)/25.911
=-1.66

MDxHealth's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-8.511-0)/27.455
=-0.31

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


MDxHealth  (NAS:MDXH) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


MDxHealth Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of MDxHealth's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


MDxHealth (MDxHealth) Business Description

Traded in Other Exchanges
N/A
Address
Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.